Press release
Cyclica Collaborates With Enamine to Use REAL Technology in Its Ligand Design Platform for AI-augmented Drug Design
TORONTO & KYIV, UKRAINE. Cyclica, Inc. announced a collaboration with Enamine Ltd., the world’s largest chemical supplier, to explore its huge readily accessible chemical space using Cyclica’s state-of-the-art AI-driven Ligand DesignTM platform. The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building blocks and 171 thoroughly validated synthesis procedures. The joint effort is expected to enable Cyclica’s Ligand DesignTM to identify novel molecules with desired polypharmacological properties out of over 11 billion REALTM (readily accessible) compounds. At least 80% of these compounds will be synthesized by Enamine within only 3-4 weeks.
Molecules produced by computers are frequently criticized by chemists who fail to find costefficient synthesis pathways to them or even question their existence because of e.g. stability issues. Enamine has changed the paradigm in accessing compounds for screening. Because of seamless control of resources (all building blocks need to be in stock at Enamine) and statistical knowledge-based enumeration of the virtual compound libraries, the REAL compounds are supplied as if they are from stock.
Cyclica’s Ligand Design technology will smartly generate REAL compounds on the fly which are predicted to bind to one or multiple targets, avoid anti-targets, and have desired ADMET and physicochemical properties, making them excellent future drug candidates. By traversing REAL space using a genetic sampling algorithm, a much larger chemical space can be accessed than is possible with conventional compound databases, leading to better candidate molecules.
Dr. Andrii Buvailo, Head of E-commerce at Enamine, commented “the REAL technology opens up access to large unexplored territory in the chemical universe of small molecules which are delivered to the bench almost like from stock. It has become a reference among our clients when it comes to virtual screening initiatives.” Michael Bossert, Head of Strategic Alliances at Enamine added: “Considering the rapidly evolving field of computational methods and techniques of Artificial Intelligence, such as machine learning and deep learning in virtual screening, we are pleased to enrich Cyclica’s approach, conveying in this manner a powerful new toolkit and pool of compounds to the early drug discovery community.”
“Bringing together Enamine’s REAL technology and Cyclica’s Ligand Design will allow our partners to obtain truly novel molecules without paying the cost of de novo synthesis, greatly increasing the speed and efficiency of drug discovery efforts,” said Dr. Andreas Windemuth, Chief Science Officer at Cyclica.
Cyclica
207 Queens Quay W, Toronto, Ontario M5J1A7, CA
Naheed Kurji
Naheed.Kurji@cyclicarx.com
Enamine
78 Chervonotkatska St. 02094 Kyiv, Ukraine
Yulia Bakanovych
y.bakanovych@enamine.net
About Cyclica
Cyclica is a Toronto-based, globally recognized biotechnology company that leverages AI and computational biophysics to reshape drug discovery. Cyclica provides the pharmaceutical industry with an integrated and end-to-end enabling drug discovery platform focused on polypharmacology. Ligand Design and Ligand Express offer a unique AI-augmented platform to design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. By doing more with artificial intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.
About Enamine
Enamine is a science-driven chemical company and provider of the world’s largest stock collections of building blocks and screening compounds. The company’s medicinal chemistry capabilities are enhanced with on-site HTS, ADMET-DMPK and early preclinical studies to provide an easily customizable integrated service package.
Molecules produced by computers are frequently criticized by chemists who fail to find costefficient synthesis pathways to them or even question their existence because of e.g. stability issues. Enamine has changed the paradigm in accessing compounds for screening. Because of seamless control of resources (all building blocks need to be in stock at Enamine) and statistical knowledge-based enumeration of the virtual compound libraries, the REAL compounds are supplied as if they are from stock.
Cyclica’s Ligand Design technology will smartly generate REAL compounds on the fly which are predicted to bind to one or multiple targets, avoid anti-targets, and have desired ADMET and physicochemical properties, making them excellent future drug candidates. By traversing REAL space using a genetic sampling algorithm, a much larger chemical space can be accessed than is possible with conventional compound databases, leading to better candidate molecules.
Dr. Andrii Buvailo, Head of E-commerce at Enamine, commented “the REAL technology opens up access to large unexplored territory in the chemical universe of small molecules which are delivered to the bench almost like from stock. It has become a reference among our clients when it comes to virtual screening initiatives.” Michael Bossert, Head of Strategic Alliances at Enamine added: “Considering the rapidly evolving field of computational methods and techniques of Artificial Intelligence, such as machine learning and deep learning in virtual screening, we are pleased to enrich Cyclica’s approach, conveying in this manner a powerful new toolkit and pool of compounds to the early drug discovery community.”
“Bringing together Enamine’s REAL technology and Cyclica’s Ligand Design will allow our partners to obtain truly novel molecules without paying the cost of de novo synthesis, greatly increasing the speed and efficiency of drug discovery efforts,” said Dr. Andreas Windemuth, Chief Science Officer at Cyclica.
Cyclica
207 Queens Quay W, Toronto, Ontario M5J1A7, CA
Naheed Kurji
Naheed.Kurji@cyclicarx.com
Enamine
78 Chervonotkatska St. 02094 Kyiv, Ukraine
Yulia Bakanovych
y.bakanovych@enamine.net
About Cyclica
Cyclica is a Toronto-based, globally recognized biotechnology company that leverages AI and computational biophysics to reshape drug discovery. Cyclica provides the pharmaceutical industry with an integrated and end-to-end enabling drug discovery platform focused on polypharmacology. Ligand Design and Ligand Express offer a unique AI-augmented platform to design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. By doing more with artificial intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.
About Enamine
Enamine is a science-driven chemical company and provider of the world’s largest stock collections of building blocks and screening compounds. The company’s medicinal chemistry capabilities are enhanced with on-site HTS, ADMET-DMPK and early preclinical studies to provide an easily customizable integrated service package.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend

/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...

/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...

/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...

/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...

/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...

/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...